AU2020348781B2 - Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases - Google Patents

Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases

Info

Publication number
AU2020348781B2
AU2020348781B2 AU2020348781A AU2020348781A AU2020348781B2 AU 2020348781 B2 AU2020348781 B2 AU 2020348781B2 AU 2020348781 A AU2020348781 A AU 2020348781A AU 2020348781 A AU2020348781 A AU 2020348781A AU 2020348781 B2 AU2020348781 B2 AU 2020348781B2
Authority
AU
Australia
Prior art keywords
compound
linker
day
group
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020348781A
Other languages
English (en)
Other versions
AU2020348781A1 (en
Inventor
Philip Stewart Low
Ramesh Mukkamala
Madduri SRINIVASARAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of AU2020348781A1 publication Critical patent/AU2020348781A1/en
Application granted granted Critical
Publication of AU2020348781B2 publication Critical patent/AU2020348781B2/en
Priority to AU2026200943A priority Critical patent/AU2026200943A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020348781A 2019-09-17 2020-09-17 Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases Active AU2020348781B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026200943A AU2026200943A1 (en) 2019-09-17 2026-02-10 Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901792P 2019-09-17 2019-09-17
US62/901,792 2019-09-17
PCT/US2020/051328 WO2021055641A1 (en) 2019-09-17 2020-09-17 Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026200943A Division AU2026200943A1 (en) 2019-09-17 2026-02-10 Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2020348781A1 AU2020348781A1 (en) 2022-04-14
AU2020348781B2 true AU2020348781B2 (en) 2025-11-27

Family

ID=74883518

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020348781A Active AU2020348781B2 (en) 2019-09-17 2020-09-17 Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases
AU2026200943A Abandoned AU2026200943A1 (en) 2019-09-17 2026-02-10 Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026200943A Abandoned AU2026200943A1 (en) 2019-09-17 2026-02-10 Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases

Country Status (11)

Country Link
US (1) US20220409747A1 (enExample)
EP (1) EP4031184A4 (enExample)
JP (2) JP2022548155A (enExample)
KR (1) KR20220066098A (enExample)
CN (1) CN114901315B (enExample)
AU (2) AU2020348781B2 (enExample)
BR (1) BR112022005013A2 (enExample)
CA (1) CA3150890A1 (enExample)
IL (1) IL291386A (enExample)
MX (1) MX2022003215A (enExample)
WO (1) WO2021055641A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
US20230147962A1 (en) * 2020-02-12 2023-05-11 Philochem Ag Fibroblast activation protein ligands for targeted delivery applications
EP4132921A4 (en) * 2020-04-09 2024-03-27 Purdue Research Foundation Pi3 kinase inhibitors and uses thereof
US20230405153A1 (en) * 2022-06-17 2023-12-21 Purdue Research Foundation Fibroblast activation protein-targeted magnetic resonance imaging agents, compositions, and methods of use
WO2023244828A1 (en) * 2022-06-17 2023-12-21 Purdue Research Foundation Fibroblast activation protein-targeted nanoparticle magnetic resonance imaging agents
KR20260005224A (ko) * 2023-03-10 2026-01-09 퍼듀 리서치 파운데이션 이중특이적 어댑터 및 종양의 치료 및 암-관련 섬유모세포의 억제에 있어서 이를 범용 car-t 세포와 함께 사용하는 용도
CN122161839A (zh) * 2024-08-23 2026-06-05 苏州博锐创合医药有限公司 基于环肽和共价弹头的化合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234431A1 (en) * 2009-03-13 2010-09-16 National Health Research Institutes Pyrrolidine compounds
WO2018111989A1 (en) * 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
WO2020083853A1 (de) * 2018-10-24 2020-04-30 Johannes Gutenberg-Universität Mainz Markierungsvorläufer mit quadratsäure-kopplung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103788071A (zh) * 2012-11-01 2014-05-14 中国人民解放军第二军医大学 N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途
KR20180103166A (ko) * 2016-01-29 2018-09-18 교와 핫꼬 기린 가부시키가이샤 핵산 복합체
JP2021500373A (ja) * 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤
JP7037667B2 (ja) * 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
PH12020551205A1 (en) * 2018-02-06 2021-04-19 Univ Heidelberg Fap inhibitors
WO2019154859A1 (en) * 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234431A1 (en) * 2009-03-13 2010-09-16 National Health Research Institutes Pyrrolidine compounds
WO2018111989A1 (en) * 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
WO2020083853A1 (de) * 2018-10-24 2020-04-30 Johannes Gutenberg-Universität Mainz Markierungsvorläufer mit quadratsäure-kopplung

Also Published As

Publication number Publication date
MX2022003215A (es) 2022-04-25
EP4031184A4 (en) 2023-12-06
AU2026200943A1 (en) 2026-02-26
CN114901315B (zh) 2025-04-29
JP2022548155A (ja) 2022-11-16
CN114901315A (zh) 2022-08-12
CA3150890A1 (en) 2021-03-25
US20220409747A1 (en) 2022-12-29
KR20220066098A (ko) 2022-05-23
EP4031184A1 (en) 2022-07-27
BR112022005013A2 (pt) 2022-06-21
JP2025131780A (ja) 2025-09-09
AU2020348781A1 (en) 2022-04-14
WO2021055641A1 (en) 2021-03-25
IL291386A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
CN114901315B (zh) 癌症和其他纤维化和炎性疾病的成纤维细胞活化蛋白(fap)靶向的成像和治疗
US20200170960A1 (en) Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
WO2021068898A1 (zh) 新颖的kras g12c蛋白抑制剂及其制备方法和用途
RU2573633C2 (ru) Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, а также применение при лечении заболеваний, вызванных аномальной активностью протеинкиназы и/или гистондеацетилазы
JP6987641B2 (ja) シリコン系薬物複合体及びその使用方法
US20180298047A1 (en) Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting
WO2021016392A1 (en) Multivalent fibroblast-targeted agents and methods of use
CN104736155B (zh) 双环化合物作为激酶的抑制剂
JP2024510267A (ja) 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法
JP2015193639A (ja) 薬物動態的改良型化合物
KR20090108086A (ko) 췌장암 치료용 조성물
WO2018148650A1 (en) Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
US20250025582A1 (en) Ligands and their use
CN118271341A (zh) Menin抑制剂及其用途
TW201113274A (en) Novel ethanediamine hepcidine antagonists
JP2022514685A (ja) ペンタミジンの類似体及びその使用
CN106317018A (zh) 一种肿瘤靶向性亲脂性阳离子‑苯丁酸氮芥化合物及制备方法和在白蛋白纳米药物中的应用
KR102068860B1 (ko) Vegfr-3 저해제의 간세포암 치료를 위한 용도
WO2021000912A1 (zh) 一类抑制egfr激酶的化合物及其制备方法和用途
WO2017024953A9 (zh) 尼莫地平水溶性衍生物及其制备方法和应用
EA051572B1 (ru) Фибробласт-активирующий белок (far)-таргетированная визуализация и терапия злокачественных опухолей и других фиброзирующих и воспалительных заболеваний
CN117460507A (zh) 靶向成纤维细胞激活蛋白的化合物及其使用方法
CN118878585A (zh) 一种靶向her2铂基抗体偶联物及其合成与肿瘤治疗的应用
CN120569387A (zh) Par2的小分子调节剂及其用途
CN119823134A (zh) 一种用于肿瘤靶向免疫治疗的小分子药物偶联物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)